登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer
ClinicalTrials.gov 上登记的一项乳腺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06313983,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Breast cancer subjects diagnosed by pathology(histology or cytology);
入选标准第 3 条
Have received radiotherapy within 4 weeks prior to study;
排除标准第 4 条
Have received chemotherapy for advanced breast cancer> 1 lines (the subjects who have used chemotherapy drugs must have stopped the chemotherapy drugs for ≥ 4 weeks before being enrolled in this study);
排除标准第 5 条
Use of any drug that inhibits or induces hepatic metabolism of Hemay022 within 2 weeks prior to study and entire study duration, for example CYP3A4 strong inhibitors or strong inducers;
排除标准第 7 条
Have received other clinical trial drugs within 4 weeks before the study
排除标准第 15 条
ECOG Performance Status of 0-1;
入选标准第 7 条
At least one lesion (measurable and/or non-measurable) that can be evaluated by CT/MRI and meets the reproducible evaluation requirements of RECIST V1.1;
入选标准第 6 条
Positive blood for human immunodeficiency virus (HIV antibody); Positive hepatitis B surface antigen and HBV-DNA>upper limit of normal; Active hepatitis C virus (HCV) infection
排除标准第 10 条
Any other malignant cancer within 5 years with the exception of adequately treated cervical cancer in situ or basal and squamous cutaneous cell carcinomas
排除标准第 18 条
Women patients of childbearing age (including their partners) have no pregnancy plan and voluntarily take effective contraceptive measures from the signing of the informed consent form to 3 months after the last medication.
入选标准第 12 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06313983,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age ≥18 years old; Subjects must give informed consent to the study before the study entry and voluntarily sign a written informed consent form; Breast cancer subjects diagnosed by pathology(histology or cytology); ER positive and HER2 over-expression (immunohistochemical IHC test 3+ and/or in situ hybridization ISH test positive);Previous test results are acceptable. Advanced/metastatic breast cancer that has previously received treatment failure with trastuzumab (or trastuzumab biosimilar) regimen;Or (new) adjuvant therapy during treatment with trastuzumab (or trastuzumab biosimilar) or within 12 months after the end of treatment, disease recurrence or progression;Patients with first-line systemic treatment for relapse (previously received trastuzumab or trastuzumab biosimilars);Or patients who are not suitable for trastuzumab treatment;Patients who have failed previous anti-HER2-ADC drug therapy can also be included. At least one lesion (measurable and/or non-measurable) that can be evaluated by CT/MRI and meets the reproducible evaluation requirements of RECIST V1.1; ECOG Performance Status of 0-1; The estimated survival time is more than 3 months; Postmenopausal women Adequate bone marrow, liver, kidney, and coagulation Bone Marrow Function (No blood transfusion or adjuvant leukocyte or platelet augmentation drugs were used within 1 week before screening) Absolute value of neutrophils (ANC) ≥1.5×109/L Hemoglobin (HB) ≥90g/L (transfusion allowed) Platelet (PLT) ≥80×109/L Liver function Liver function grade Child-Pugh A/B (≤9 points) Alanine transferase (ALT) or aspartate aminotransferase (AST) ≤2.5 ULN in the absence of liver metastasis; ALT or AST≤ 5x ULN with liver metastasis Renal function: serum creatinine ≤1.5 times ULN; All previous treatment-related toxicities must be CTCAE (version 5.0) ≤ Grade 2 at the time of randomization, except for hair loss, pigmentation, and long-term toxicity caused by radiotherapy (which cannot be recovered by the investigator's judgment); Women patients of childbearing age (including their partners) have no pregnancy plan and voluntarily take effective contraceptive measures from the signing of the informed consent form to 3 months after the last medication.排除标准:Exclusion Criteria:
Patients with visceral crisis(Visceral crisis is defined as the dysfunction of several organs confirmed by symptoms, signs, laboratory tests, and rapid disease progression.Visceral crisis does not simply refer to the presence of visceral metastases, but to critical visceral conditions that require rapid and effective treatment to control the disease progression, especially when the opportunity for chemotherapy is lost after progression) Patients with the presence of spinal cord compression or brain, meningeal metastases Patients who have been treated with a small molecule HER2 tyrosine kinase inhibitor (HER2-TKI) (medication course ≤2 weeks is excluded) Have received radiotherapy within 4 weeks prior to study; Have received chemotherapy for advanced breast cancer> 1 lines (the subjects who have used chemotherapy drugs must have stopped the chemotherapy drugs for ≥ 4 weeks before being enrolled in this study); Patients with parenteral nutrition; malabsorption syndrome; or any condition possibly affecting drug absorption or inability to tolerate oral medications; Use of any drug that inhibits or induces hepatic metabolism of Hemay022 within 2 weeks prior to study and entire study duration, for example CYP3A4 strong inhibitors or strong inducers; Patients who are known to have a history of allergies to Hemay022, lapatinib、AI (letrozole, exemestane) capecitabine or similar drugs. Left ventricular ejection fraction (LVEF) <50% as measured by echocardiogram or MUGA scan. Positive blood for human immunodeficiency virus (HIV antibody); Positive hepatitis B surface antigen and HBV-DNA>upper limit of normal; Active hepatitis C virus (HCV) infection Patients with active infection requiring intravenous anti-infective treatment Arrhythmias requiring treatment , including atrial fibrillation, supraventricular tachycardia ,ventricular tachycardia, ventricular fibrillation, or patients with coronary heart disease have symptoms requiring medicine treatment, myocardial infarction within 1 year, congestive heart failure (CHF) Confirmed QTc prolongation (≥500ms) (heart rate corrected according to Bazett formula or Fridericia formula) People with a history of interstitial lung disease that needs treatment, a history of radiation pneumonitis, or clinically active interstitial lung disease Have received other clinical trial drugs within 4 weeks before the study Major surgery or injury less than 4 weeks before the study The study period must be accompanied by other antitumor therapy,such as chemotherapy, targeted therapy, hormone therapy, immunotherapy, radiotherapy (except symptomatic local radiotherapy) Any other malignant cancer within 5 years with the exception of adequately treated cervical cancer in situ or basal and squamous cutaneous cell carcinomas Any condition that would make the subject inappropriate for this study by the investigator's judgment
引自 ClinicalTrials.gov, NCT06313983, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06313983,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。